Sinopharm Capital

4inLook is a retailer specializing in color contact lenses, operating over 300 stores across first- and second-tier cities in China. Founded in 2008 and based in Shanghai, the company offers more than 200 distinct designs tailored primarily for women aged 18 to 30. In addition to its brick-and-mortar presence, 4inLook has expanded its reach through online channels, including a Tmall store, providing a seamless shopping experience that integrates online ordering with offline product trials and pick-up options. The company focuses on enhancing the aesthetic appeal of its customers' eyes while making cosmetic products accessible and affordable.

Metanovas Biotech is a company focused on developing innovative nutraceutical and cosmeceutical products using advanced artificial intelligence technology. Their product pipeline encompasses pharmaceuticals, nutritional supplements, functional foods, and cosmetics, aimed at enhancing the health and well-being of patients and consumers. Metanovas employs a sophisticated AI-enabled platform for drug and disease discovery, utilizing machine learning to identify novel disease targets, screen potential drugs, and repurpose existing medications for new applications. This approach allows for optimized drug development and improved insights into disease biology, ultimately leading to the creation of more effective health products.

Artivila Therapeutics is a pharmaceutical company based in Shenzhen, China, founded in 2018. It specializes in the research and development of new drugs, focusing on therapeutic solutions for neurodegenerative diseases, cancers, and autoimmune diseases. The company leverages an AI-powered drug discovery engine to create an innovative platform that enables the consistent and efficient development of first-in-class molecules. Artivila Therapeutics aims to enhance patients' lives through advanced biotechnology and targeted therapeutics.

CytoNiche is a biotechnology company focused on the development of 3D micro-organization engineering technology, primarily for stem cell research. Originating from advancements at Tsinghua University, the company specializes in creating high-quality stem cell cultures and injectable 3D micro-tissue treatments. CytoNiche offers a range of innovative products and services, including automated and intelligent stem cell culture amplification processes and 3D cell high-throughput drug screening tools. Its solutions are designed to support research institutes, clinical organizations, stem cell companies, and drug research enterprises, providing reliable 3D micro-tissue products essential for advancing drug development and regenerative medicine.

Xishan is a medical device company based in Chongqing, China, specializing in the research, development, manufacturing, and sale of surgical instruments. Founded in 1992, it focuses on minimally invasive surgical tools and provides essential equipment for various surgical operations, including neurosurgery, orthopedics, ENT, and plastic surgery. The company's main offerings include surgical power devices, endoscope systems, and consumables designed for procedures such as bone cutting, grinding, and milling. With a commitment to advancing surgical technology, Xishan plays a significant role in enhancing surgical efficacy and patient outcomes in hospitals.

Sumgen is an antibody drug developer focused on creating innovative therapeutic antibody drugs for the treatment of tumors and other diseases. The company specializes in immunotherapy and immunodiagnosis, employing advanced technologies such as computer-aided design and mammalian cell display to screen and optimize antibody candidates. By leveraging its unique research and development methodologies, Sumgen aims to produce effective antibody drugs that provide patients with targeted treatment options for major diseases, including cancer.

Longhui Medical is a medical robotics R&D company focused on joint replacement surgery robots, product development, sales, and service.

Sepax Technologies is a biotechnology company specializing in the development of chromatography products for the separation and purification of pharmaceuticals and biologics. The firm provides a variety of products, including liquid chromatography columns, bulk resins, and systems that support multiple modalities such as size exclusion chromatography, ion exchange, hydrophobic interaction chromatography, affinity chromatography, and reversed-phase chromatography. By offering these innovative solutions, Sepax Technologies enables biological researchers and scientists to achieve high-resolution, high-efficiency, and high-recovery separations of proteins, oligonucleotides, peptides, and other biomolecules, thus advancing research and development in the life sciences sector.

Shanghai Ouyi Biomedical Technology Co., Ltd., established in 2009, is a high-tech enterprise of multi-omics testing services with "specialization, specialization and new". It has built a multi-omics testing platform covering nucleic acid, protein, and metabolism. Big data analysis platform combined with multi-omics. For pharmaceutical, food and daily chemical companies; life sciences, medicine and clinical research fields, provide drug target discovery, pharmacological efficacy and safety evaluation, disease molecular marker screening, pathogenic bacteria and drug resistance traceability, life development research and Multi-level and multi-omics testing services and solutions for disease occurrence and development research.

Brise Pharma is a scientific research company specializing in developing novel biopharmaceutical drugs for treating pain. Its primary focus lies in creating innovative and distinct analgesic treatments targeting migraine, neuropathic, and musculoskeletal pain, aiming to provide safe, effective, and accessible pain relief solutions globally.

Geneus develops and commercializes gene sequencers and reagents. The core of its technology is based on the characteristic current signal generated by the interaction of protein nanopores and nucleic acid bases, and it realizes single-molecule nucleic acid sequencing through an integrated chip system.

Yikon Genomics Co., Ltd. is a Beijing-based company specializing in the development and supply of genetic analytical products and services focused on single-cell sequencing. Established in 2012, Yikon utilizes patented MALBAC technology to offer a range of solutions aimed at improving reproductive health and cancer diagnostics, including liquid tumor biopsy. Its product line features the MALBAC single cell whole genome amplification kit, along with companion kits designed for various applications such as copy number variation and single nucleotide variant analysis. The company also provides services such as single-cell DNA genome sequencing and whole human genome re-sequencing. Yikon's innovation has been significant in the fields of prenatal and postnatal care as well as early tumor detection, empowering healthcare professionals with accurate and efficient diagnostic tools.

FutureGen is a biopharmaceutical company focused on the development of innovative biologics, specifically in the fields of immunology and cancer. The company is dedicated to creating and commercializing novel antibody drugs aimed at improving treatment outcomes for cancer and tumor-related diseases. FutureGen utilizes its proprietary Structure-based Targeted Evolution Platform, which is an advanced screening technology designed for efficient protein drug screening. This platform allows for the rapid identification and production of optimal antibodies. With a strong background in medication development, clinical research, and quality management, FutureGen aims to enhance treatment options for patients through its groundbreaking research and development efforts.

Beijing Biostar Technologies, Ltd., established in 2002, is a biopharmaceutical company based in Beijing, China. It specializes in the development of anti-tumor chemotherapy biopharmaceutical molecules, with a focus on creating innovative small molecule chemical drugs for cancer treatment. The company was founded by a team of Chinese scientists led by Dr. Tang Li and Dr. Qiu Rongguo, who previously worked in the United States. Biostar Technologies pioneered the creation of new anti-cancer drugs based on epothilone in China and its technology is recognized as being at the international advanced level.

Huiyi Huiying is an international cloud computing, large data & AI tech that has created a digital medical imaging and tumor radiotherapy platform. It has also built a video intelligent screening system, leak detection system and the image Depth applied to the tumor, cardiovascular, acute abdomen and other single disease of artificial intelligence assisted diagnosis and treatment system.

Kira Pharmaceuticals, established in 2017 and headquartered in Suzhou, China, is a biotechnology company focused on developing innovative therapies targeting the complement system to treat immune-mediated diseases.

Dingdang Kuaiyao is an online-to-offline drug purchasing and delivery platform. After users place orders on the mobile app, drugs will be delivered to their homes within half an hour.

MEDx is a company specializing in precision medicine solutions aimed at enhancing clinical development. Founded in 2013 and headquartered in Suzhou, Jiangsu, MEDx employs translational science to advance diagnostic technologies related to nucleic acids and proteins. Its comprehensive services include biomarker development, Companion Diagnostics, Point-of-Care development, clinical testing, and the commercialization of medical products. By focusing on individualized treatment, MEDx seeks to improve patient outcomes through its innovative approaches in the healthcare sector.

Bichen Pharmaceutical is a small-molecule tumor-targeted drug developer for the treatment of various malignant tumors and brain metastases.

Jinfang Pharmaceutical is focused on R&D and drug development from small molecule drug pipelines to diversified cutting-edge therapies.

SinoTau is a comprehensive solution provider in the pharmaceutical sector, focusing on both generic and innovative drugs. The company specializes in the early development of antibody biopharmaceuticals and produces advanced generic medications. It aims to address various therapeutic areas, including cardiovascular diseases, neurodegeneration, and tumors. SinoTau's expertise encompasses medicinal chemical synthesis, generic drug analysis, pharmaceutical preparations, and drug registration, supported by leading research in targeted drug development. The company leverages advanced diagnostic methods and monoclonal antibody technologies to enhance its offerings, positioning itself as a key player in the biotechnology industry.

GenFleet Therapeutics, established in 2017 and headquartered in Shanghai, China, is a biotechnology company focused on cancer research and development. It specializes in creating therapeutic molecules, including signal transduction regulators, tumor microenvironment modulators, and transcription factors, to target various cancer systems. The company aims to develop innovative molecular-level pharmaceuticals and antibody drugs that can effectively stimulate the body's immune response against tumors. GenFleet serves both domestic and international clients.

ArteryFlow is a developer of advanced diagnostic systems that leverage artificial intelligence, computational fluid dynamics, and 3D medical image reconstruction. The company specializes in creating software for analyzing CT scans and ECG results, which enhances the ability of healthcare professionals to deliver faster and more precise diagnoses. By integrating big data technologies, ArteryFlow offers intelligent and image-assisted diagnostic solutions, along with technical training and guidance for users across various sectors, including scientific research institutions, hospitals, and clinics. The company's innovative approach includes automated grid generation and virtual therapy, aiming to improve diagnostic accuracy and efficiency in medical settings.

Baicare is a biotechnology company focused on enhancing clinical microbiological testing and promoting the rational use of antibiotics. Utilizing microfluidic chips and gene detection technology, Baicare develops intelligent automated nucleic acid detection products for clinical hospitals. Their innovative chips can rapidly and accurately identify pathogenic bacteria and assess drug resistance, thereby enabling healthcare providers to formulate effective treatment plans. This approach not only alleviates patient suffering but also aims to significantly reduce healthcare costs. The company has experienced rapid growth, securing substantial financial support, including recognition as a "National High-Tech Enterprise." Baicare has filed for over 20 related patents and has garnered attention from both medical experts and investors, underscoring its commitment to improving diagnostics for infectious and genetic diseases.

Synyi is a provider of an artificial intelligence-powered medical data platform designed to enhance medical research, healthcare, and patient services through big data applications. The company leverages advanced natural language processing technology to structure and standardize medically related texts, employing techniques such as lexical, syntactic, and semantic analysis, as well as structured expression and standardized mapping. This innovative approach enables hospitals to access smart medical systems, improving the efficiency and effectiveness of healthcare delivery. The team at Synyi consists of experts from prestigious universities and renowned companies, with a strong background in artificial intelligence, medicine, and medical informatics. Their technical achievements have been recognized through numerous publications in leading international journals and presentations at major medical conferences.

Novena Global Lifecare is a unique integrated Healthcare platform.

Suzhou And Science Technology Development Corp is a manufacturer of surgical instruments and medical devices, established in 2006 and headquartered in Zhangjiagang, China. The company specializes in developing products for various medical settings, including operating rooms, emergency rooms, and treatment rooms. Its product lineup features the "AND" brand, which includes a minimally invasive vertebroplasty system, medical vacuum drainage systems, high-pressure pulse irrigation systems, single-use irrigators, external fixation systems, and DC orthopedic drill chainsaws. Through its innovative offerings, the company aims to enhance medical procedures and improve patient outcomes.

Dingdang Kuaiyao is an online-to-offline drug purchasing and delivery platform. After users place orders on the mobile app, drugs will be delivered to their homes within half an hour.

Kanglu Bio is positioned to provide clinical diagnosis and guidance for clinical drug molecular diagnostic products and clinical molecular diagnostics overall service providers for clinical hospitals and third-party clinical independent testing institutions. The products and services are mainly used in cardiovascular and cerebrovascular diseases. Major diseases such as tumors and cancer.

Skynor Medical is a supplier of medical equipment. Their products include peripheral vascular stent systems, distal access catheters, microcatheters, thrombectomy devices, and balloon dilatation catheters.

Virogin Biotech Ltd., founded in 2015 and based in Vancouver, Canada, specializes in the development of oncolytic virus therapeutics aimed at treating cancer. The company utilizes its innovative Synerlytic™ technical platform to enhance cancer treatment through novel immunotherapy approaches. Virogin's technology focuses on leveraging immunological principles to stimulate anticancer and antitumor immunity. By harnessing a robust and transient antiviral immune response, the company aims to improve systemic antitumor immunity via synergistic interactions with multiple therapeutic payloads. Virogin is dedicated to advancing its position as a leader in the field of immuno-oncology.

GenFleet Therapeutics, established in 2017 and headquartered in Shanghai, China, is a biotechnology company focused on cancer research and development. It specializes in creating therapeutic molecules, including signal transduction regulators, tumor microenvironment modulators, and transcription factors, to target various cancer systems. The company aims to develop innovative molecular-level pharmaceuticals and antibody drugs that can effectively stimulate the body's immune response against tumors. GenFleet serves both domestic and international clients.

Dr. Yu Pediatrics Clinics is a healthcare provider located in Chongqing, China, specializing in pediatric care. The clinic focuses on delivering comprehensive medical services to children, addressing a wide range of health concerns from routine check-ups to more specialized treatments. By prioritizing the well-being of young patients, Dr. Yu Pediatrics Clinics aims to create a supportive environment for families, ensuring that children receive quality healthcare tailored to their specific needs. The clinic is dedicated to fostering healthy development and managing pediatric health issues effectively.

LinaTech is a healthcare company specializing in the development and manufacturing of precision radiotherapy equipment for tumor treatment. The company creates informatics software designed to enhance the management of cancer clinics, radiotherapy centers, and medical oncology practices. Additionally, LinaTech produces image guidance series products and stereotactic radiotherapy equipment, equipping medical institutions with advanced tools for the calculation, positioning, treatment, and verification of radiotherapy procedures. Through its innovative solutions, LinaTech aims to improve the effectiveness and accuracy of cancer treatment.

Eccogene is a clinical stage biopharmaceutical company focused on developing therapeutic solutions for unmet medical needs, particularly in the areas of metabolic and immune-related diseases. The company specializes in disease biology, medicinal chemistry, and translational science, with the aim of creating innovative pharmaceuticals that target complex chronic conditions such as obesity and diabetes. Eccogene is dedicated to advancing its pipeline of metabolic drugs to enhance patient outcomes and address significant health challenges.

Topsuper specializes in R&D, production and sales of medical equipment.

Ansun Biopharma, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative therapies to prevent and treat severe human diseases. The company specializes in host-directed anti-viral therapies aimed at addressing respiratory viral infections, such as influenza and parainfluenza viruses, by targeting the host rather than the virus itself. Its product pipeline includes Fludase, which is designed for the prophylaxis and treatment of influenza-related respiratory infections, and Viradin, an intravenous therapeutic for sepsis and viral hemorrhagic fever caused by pathogens like Ebola and Marburg viruses. Additionally, Ansun Biopharma has developed TOSAP, a technology for creating microspheres and nanospheres for drug delivery. Founded in 2003 and originally named NexBio, Inc., the company rebranded to Ansun Biopharma in 2011, reflecting its commitment to addressing critical health challenges through advanced biopharmaceutical solutions.

Eyebright Medical Technology (Beijing) Co Ltd is dedicated to the research, development, production, and sales of ophthalmic medical devices aimed at improving eye health and vision. The company offers a diverse range of products, including intraocular lenses, IOL delivery systems, surgical instruments, optometric lenses, and eye drops, all designed to address various ophthalmic conditions such as cataracts, glaucoma, and refractive errors. In addition to its product offerings, Eyebright provides related services to support the effective use of its medical devices, contributing to advancements in eye care and treatment.

LYNK Pharmaceuticals is a biotechnology company based in Hangzhou, China, specializing in the development of small molecule drugs aimed at treating tumors and autoimmune diseases. Founded in 2017, the company focuses on the discovery and development of innovative medicines in the fields of oncology, immunology, and inflammatory diseases. Its business operations include new drug research, sales, and activities related to patent authorization and transfer.

Ancare Medical operates a network of clinics dedicated to addressing psychological health issues. The company offers a range of services, including online psychological consultations, intelligent rehabilitation assistance, and the diagnosis and treatment of psychological disorders. By focusing on both the symptoms and underlying causes of psychological distress, Ancare aims to help individuals achieve improved mental well-being and a better quality of life. Through its comprehensive approach to psychological healthcare, Ancare Medical seeks to provide effective support and treatment for patients facing mental health challenges.

Virtual Incision is a medical technology company focused on developing innovative robotic-assisted surgical devices, specifically targeting colon resection. The company has created the MIRA (Miniaturized In vivo Robotic Assistant) Platform, which is a pioneering miniaturized surgical robotic support device. This platform allows for efficient operating room setups in minutes, eliminating the need for cumbersome equipment handling such as draping or docking. By enhancing the surgical process, Virtual Incision aims to improve clinical outcomes while also addressing healthcare costs, positioning itself as a leader in the field of robotic-assisted surgery.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Abbisko Therapeutics Co. Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on the discovery, development, and manufacturing of innovative immuno-oncology therapies. Founded in 2016 by a team of experienced professionals from leading pharmaceutical companies, Abbisko is dedicated to developing small molecule inhibitors, including ABSK011 and ABSK021, for the treatment of hepatocellular carcinoma, as well as CSF1R for solid tumors. In addition to oncology, the company is engaged in developing therapeutics for various conditions, including cancer, liver diseases, diabetes, metabolic disorders, viral infections, and central nervous system diseases.

Joymed Technology specializes in the research and development, registration, and manufacturing of medical devices, providing comprehensive solutions tailored for medical equipment businesses. The company focuses on delivering innovative and reliable technology while ensuring high-quality standards in its products. By offering services such as device design, risk management, marketing, and product verification and validation, Joymed Technology enables its clients to develop and launch safe and affordable medical products efficiently. The company aims to become a trusted partner for both domestic and international medical device firms, particularly assisting small and medium-sized enterprises in navigating the complexities of the medical product market. Through flexible collaboration and optimized design processes, Joymed Technology seeks to accelerate mutual growth with its customers.

InventisBio Inc. is a biotechnology company focused on discovering and developing innovative therapeutics for cancer and metabolic diseases. Founded in 2013 and based in Pudong, China, the company has developed a range of small molecule drug candidates targeting lung cancer, breast cancer, and gout. Among its notable products is D-0316, a third-generation EGFR-T790M tyrosine kinase inhibitor. InventisBio is also engaged in creating targeted immuno-oncology therapies that can be used in combination with existing treatments, such as PD-1 antibodies, to address various cancer indications. Co-founded by Dr. Yaolin Wang and a team of scientists with extensive experience in drug discovery at major pharmaceutical companies, InventisBio aims to provide effective therapies for significant health challenges.

FHNED is a company that offers a range of seawater desalination products and services. Their products include sea dew sea hydrogen water, hai dew still sparkling water, marine ecological water, compound fruit and vegetable juice drink, and more. The company's contact modes are mail, phone, and physical address.

Anbiping is a number of reagents and supporting devices have indeed been independently created by Anbiping, which focuses on tumour screening and correct diagnosis. Pathology is the main application department. It has been established that product lines for liquid-based cytology, polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization can be used to screen for and diagnose tumors based on everything from cell morphology to protein expression.

ZC511.com information is gathered, categories and services are provided, and the information flow, commodity flow, financial flow, and distribution flow are created by the pharmaceutical industry chain. Chinese patent medicines, chemical drug preparations, chemical raw materials, antibiotic preparations, antibiotic raw materials, biochemical medications, biological products, chinese medicinal materials, chinese herbal components, and other items are all part of their business.